RxDoctor Payments Data

Elana Clar, MD

Neurology · Paramus, NJNPI 1033484209

Payments from drug & device makers

$12,980in general payments, 2019–2025

Across 162 payments — averaging $80.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amneal Pharmaceuticals LLC$8K
  • Abbott$4K
  • MDD US Operations, LLC$891
  • Insightec,inc$342
  • SK Life Science, Inc.$147
  • Boston Scientific$111
  • plus $174 from 5 others
$508in research payments, 2019–2025

Across 1 payment — averaging $507.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$508

What the payments were for

  • Consulting fees$3253%
  • Speaking & faculty fees$6,37549%
  • Travel & lodging$3543%
  • Food & beverage$4,90638%
  • Education$1,0208%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,980 in reported general payments places this provider in the 70th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$173,771
Medicare patients
227
Services billed
11,789

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate83$453,873
RytaryCarbidopa/Levodopa129$191,254
NeuproRotigotine31$58,837
Carbidopa-LevodopaCarbidopa/Levodopa756$48,060
NourianzIstradefylline24$44,573
GocovriAmantadine Hcl24$38,844
AmantadineAmantadine Hcl159$14,387
XadagoSafinamide Mesylate11$12,447
MyrbetriqMirabegron14$12,285
Selegiline Hcl81$11,574
Carbidopa-Levodopa ErCarbidopa/Levodopa181$7,793
Ropinirole ErRopinirole Hcl22$6,296
Escitalopram Oxalate145$2,732
Mirtazapine53$2,552
Quetiapine Fumarate81$2,175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$7,769$191,254129 claims
MDD US Operations, LLCGocovri$891$38,84424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 521 neurology providers in New Jersey.

Other neurology in Paramus

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →